Cargando…
Fibrin-derived peptide Bβ15-42 (FX06) as salvage treatment in critically ill patients with COVID-19-associated acute respiratory distress syndrome
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7512215/ https://www.ncbi.nlm.nih.gov/pubmed/32972429 http://dx.doi.org/10.1186/s13054-020-03293-8 |
| _version_ | 1783586106333200384 |
|---|---|
| author | Adam, Elisabeth H. Schmid, Benedikt Sonntagbauer, Michael Kranke, Peter Zacharowski, Kai Meybohm, Patrick |
| author_facet | Adam, Elisabeth H. Schmid, Benedikt Sonntagbauer, Michael Kranke, Peter Zacharowski, Kai Meybohm, Patrick |
| author_sort | Adam, Elisabeth H. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7512215 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-75122152020-09-24 Fibrin-derived peptide Bβ15-42 (FX06) as salvage treatment in critically ill patients with COVID-19-associated acute respiratory distress syndrome Adam, Elisabeth H. Schmid, Benedikt Sonntagbauer, Michael Kranke, Peter Zacharowski, Kai Meybohm, Patrick Crit Care Research Letter BioMed Central 2020-09-24 /pmc/articles/PMC7512215/ /pubmed/32972429 http://dx.doi.org/10.1186/s13054-020-03293-8 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| spellingShingle | Research Letter Adam, Elisabeth H. Schmid, Benedikt Sonntagbauer, Michael Kranke, Peter Zacharowski, Kai Meybohm, Patrick Fibrin-derived peptide Bβ15-42 (FX06) as salvage treatment in critically ill patients with COVID-19-associated acute respiratory distress syndrome |
| title | Fibrin-derived peptide Bβ15-42 (FX06) as salvage treatment in critically ill patients with COVID-19-associated acute respiratory distress syndrome |
| title_full | Fibrin-derived peptide Bβ15-42 (FX06) as salvage treatment in critically ill patients with COVID-19-associated acute respiratory distress syndrome |
| title_fullStr | Fibrin-derived peptide Bβ15-42 (FX06) as salvage treatment in critically ill patients with COVID-19-associated acute respiratory distress syndrome |
| title_full_unstemmed | Fibrin-derived peptide Bβ15-42 (FX06) as salvage treatment in critically ill patients with COVID-19-associated acute respiratory distress syndrome |
| title_short | Fibrin-derived peptide Bβ15-42 (FX06) as salvage treatment in critically ill patients with COVID-19-associated acute respiratory distress syndrome |
| title_sort | fibrin-derived peptide bβ15-42 (fx06) as salvage treatment in critically ill patients with covid-19-associated acute respiratory distress syndrome |
| topic | Research Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7512215/ https://www.ncbi.nlm.nih.gov/pubmed/32972429 http://dx.doi.org/10.1186/s13054-020-03293-8 |
| work_keys_str_mv | AT adamelisabethh fibrinderivedpeptidebb1542fx06assalvagetreatmentincriticallyillpatientswithcovid19associatedacuterespiratorydistresssyndrome AT schmidbenedikt fibrinderivedpeptidebb1542fx06assalvagetreatmentincriticallyillpatientswithcovid19associatedacuterespiratorydistresssyndrome AT sonntagbauermichael fibrinderivedpeptidebb1542fx06assalvagetreatmentincriticallyillpatientswithcovid19associatedacuterespiratorydistresssyndrome AT krankepeter fibrinderivedpeptidebb1542fx06assalvagetreatmentincriticallyillpatientswithcovid19associatedacuterespiratorydistresssyndrome AT zacharowskikai fibrinderivedpeptidebb1542fx06assalvagetreatmentincriticallyillpatientswithcovid19associatedacuterespiratorydistresssyndrome AT meybohmpatrick fibrinderivedpeptidebb1542fx06assalvagetreatmentincriticallyillpatientswithcovid19associatedacuterespiratorydistresssyndrome |